Summary of Guidelines for Managing Histoplasmosis among
People Living with HIV

Freddy Perez; Diego H Caceres; Nathan Ford; Giovanni Ravasi; Beatriz L Gomez; Alessandro C Pasqualotto; Paul Hine; Antoine A Adenis; Mathieu Nacher; Tom Chiller; John Badley

doi:10.3390/jof7020134

Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

Freddy Perez, Diego H Caceres, Nathan Ford, Giovanni Ravasi, Beatriz L Gomez, Alessandro C Pasqualotto, Paul Hine, Antoine A Adenis, Mathieu Nacher, Tom Chiller, John Badley

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

Abstract: Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population.

In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed by

a maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviral

therapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis and

tuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policy

guidance for the care of PLHIV are required.

Original language	English
Article number	134
Pages (from-to)	1-8
Number of pages	8
Journal	Journal of Fungi
Volume	7
Issue number	2
DOIs	https://doi.org/10.3390/jof7020134
Publication status	Published - 12 Feb 2021

Keywords

Advanced HIV disease
Diagnosis
Guidelines
Histoplasma
Histoplasmosis
Pan American Health Organization (PAHO)
World health Organization (WHO)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jof7020134Licence: CC BY

Perez-2021-Summary-of-guidelines-for-managing-Final published version, 966 KBLicence: CC BY

Cite this

@article{fe77c04b9b3644bea332751fcf45e54e,

title = "Summary of Guidelines for Managing Histoplasmosis among People Living with HIV",

abstract = "Abstract: Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5\% to 15\% of AIDS-related deaths among this population.In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed bya maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviraltherapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis andtuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policyguidance for the care of PLHIV are required.",

keywords = "Advanced HIV disease, Diagnosis, Guidelines, Histoplasma, Histoplasmosis, Pan American Health Organization (PAHO), World health Organization (WHO)",

author = "Freddy Perez and Caceres, \{Diego H\} and Nathan Ford and Giovanni Ravasi and Gomez, \{Beatriz L\} and Pasqualotto, \{Alessandro C\} and Paul Hine and Adenis, \{Antoine A\} and Mathieu Nacher and Tom Chiller and John Badley",

year = "2021",

month = feb,

day = "12",

doi = "10.3390/jof7020134",

language = "English",

volume = "7",

pages = "1--8",

journal = "Journal of Fungi",

issn = "2309-608X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

AU - Perez, Freddy

AU - Caceres, Diego H

AU - Ford, Nathan

AU - Ravasi, Giovanni

AU - Gomez, Beatriz L

AU - Pasqualotto, Alessandro C

AU - Hine, Paul

AU - Adenis, Antoine A

AU - Nacher, Mathieu

AU - Chiller, Tom

AU - Badley, John

PY - 2021/2/12

Y1 - 2021/2/12

N2 - Abstract: Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population.In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed bya maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviraltherapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis andtuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policyguidance for the care of PLHIV are required.

AB - Abstract: Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population.In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed bya maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviraltherapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis andtuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policyguidance for the care of PLHIV are required.

KW - Advanced HIV disease

KW - Diagnosis

KW - Guidelines

KW - Histoplasma

KW - Histoplasmosis

KW - Pan American Health Organization (PAHO)

KW - World health Organization (WHO)

U2 - 10.3390/jof7020134

DO - 10.3390/jof7020134

M3 - Article

SN - 2309-608X

VL - 7

SP - 1

EP - 8

JO - Journal of Fungi

JF - Journal of Fungi

IS - 2

M1 - 134

ER -